Myriad Genetics Stock
Myriad Genetics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Country
- United States
- CEO
- Samraat S. Raha
- Employees
- 2,700
- Market cap
- $381 M
- IPO
- 06/10/1995
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx…
Myriad Genetics stock: price history
1D
-8.5%
1W
-7.7%
1M
+3.1%
6M
-21.7%
YTD
-35.3%
1Y
-50.7%
2Y
-83.4%
5Y
-87.5%
10Y
-78.6%
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~165% stronger price swings than usual
Ask the agents about Myriad Genetics
Analyst assessment of Myriad Genetics
PRICE TARGET LOW
US$2.00
CONSENSUS
US$3.92
MEDIAN
US$3.00
PRICE TARGET HIGH
US$8.00
0
STRONG BUY
8
BUY
22
HOLD
7
SELL
0
STRONG SELL
37
TOTAL · Hold
As of: 13/10/2026
Myriad Genetics stock metrics
P/E
-3.33
P/B
1.24
EV/EBITDA
-10.53
RETURN ON EQUITY
-14.2%
NET MARGIN
-22.7%
DEBT/EQUITY
0.69
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
92.6%
FLOAT SHARES
88,604,720
AVG. DAILY VOLUME (30D)
1,996,734
Insider transactions (SEC)
Wheeler Benjamin Richard
Sikri Vishal
Fox Jennifer Lynne
Wheeler Benjamin Richard
Raha Samraat S.
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about Myriad Genetics stock
What does Myriad Genetics do?
Myriad Genetics, Inc. is a company in the Healthcare sector, Medical - Diagnostics & Research industry, headquartered in United States.
The CEO is Samraat S. Raha, the company employs around 2,700 people.
The IPO was on 06/10/1995; the stock trades on NASDAQ under the ticker MYGN.
What do analysts say about Myriad Genetics stock?
37 analysts rate the stock, the consensus is Hold (as of 13/10/2026).
The average price target is US$3.92, ranging from US$2.00 to US$8.00, with a median of US$3.00.
This is an external assessment, not a statement by Market Jury.
When does Myriad Genetics report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 165% stronger than usual.
Does Myriad Genetics pay a dividend?
Yes. The last dividend was US$1.75 per share.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to Myriad Genetics?
Comparable stocks include Thermo Fisher Scientific, Danaher, Natera, Agilent Technologies, IQVIA Holdings, Waters, Illumina and IDEXX Laboratories.
How can I get Myriad Genetics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Myriad Genetics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.